Home » Topics » Regulatory

Regulatory
RSS

First approval for Pharmacyclics' MRI contrast agent

Dec. 12, 1996

NMDA antagonists ameliorate ototoxicity of aminoglycoside antibiotics

Dec. 12, 1996

Janssen files for lower-dose risperidone in U.S.

Dec. 12, 1996

Cholesterol-lowering statin approved in first markets

Dec. 11, 1996

OsmoCyte approved for marketing in U.S.

Dec. 9, 1996

Cytovene approved for new indication in U.S.

Dec. 6, 1996

Once-daily antihypertensive combination cleared for marketing in Canada

Dec. 3, 1996

First approval for Aricept

Nov. 27, 1996

Water-soluble fiber introduced in first market for high cholesterol

Nov. 27, 1996

Lilly claims 5-HT7 antagonist for GI indications

Nov. 26, 1996

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....